Matsumoto T, Kubo S, Haraoka M, Takahashi K, Tanaka M, Sakumoto M, Kumazawa J
Department of Urology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Clin Ther. 1993 Sep-Oct;15(5):819-28.
To determine the bacterial and clinical effects of methicillin-resistant Staphylococcus aureus (MRSA) on urinary tract infection (UTI), postoperative wound infection, and bacteremia, 22 strains of MRSA from infected patients were examined; minimal inhibitory concentration (MIC), fractional inhibitory concentration (FIC) index, coagulase typing, and change in MIC in the combination of cefuzonam (CZON) and fosfomycin (FOM) or minocycline (MINO), and the clinical effects of the combination therapy of CZON+FOM or CZON+MINO were investigated in 23 patients. MIC distribution was assessed for 11 drugs: methicillin (DMPPC), cefazolin (CEZ), cefotiam (CTM), cefuzonam (CZON), minocycline (MINO), vancomycin (VCM), arbekacin (ABK), imipenem (IPM), fosfomycin (FOM), ofloxacin (OFLX), and clarithromycin (CAM). For VCM and ABK, MICs ranged from 0.2 to 12.5 micrograms/ml. MINO showed a wide range of MIC, from 0.05 to 25 micrograms/ml. All strains were less sensitive to other antimicrobials. This MIC distribution was assessed in categories by coagulase typing. For CAM, type II strains revealed > or = 100 micrograms/ml of MIC50 and MIC90 compared with 0.2 and 3.13 micrograms/ml in type VII strains. For mixed combinations of CZON and MINO at ratios of 10 to 1 and 40 to 1, the rates of blood concentration for drugs 10 and 120 min after the intravenous injection, MIC distribution was observed between MINO and CZON. For mixed combinations of CZON and FOM at ratios of 1 to 1 and 1 to 4, MIC distribution was more sensitive than for FOM or CZON alone. With respect to the clinical effects of combination therapy by CZON+MINO and CZON+FOM, of seven cases of UTI with CZON+MINO, MRSA was eliminated completely in 4 patients (57.1%). In all patients who received CZON+FOM, MRSA was completely eliminated by this treatment regimen. In 4 of 7 (57.1%) patients with would infection and bacteremia, MRSA was eliminated by the combination of CZON+FOM or CZON+MINO. These results suggest that CZON+FOM is an effective combination in treating UTI and other MRSA infections in urology.
为确定耐甲氧西林金黄色葡萄球菌(MRSA)对尿路感染(UTI)、术后伤口感染及菌血症的细菌学和临床影响,对22株来自感染患者的MRSA菌株进行了检测;研究了头孢唑肟(CZON)与磷霉素(FOM)或米诺环素(MINO)联合使用时的最低抑菌浓度(MIC)、部分抑菌浓度(FIC)指数、凝固酶分型以及MIC变化,并对23例患者采用CZON+FOM或CZON+MINO联合治疗的临床效果进行了研究。评估了11种药物的MIC分布:甲氧西林(DMPPC)、头孢唑林(CEZ)、头孢替安(CTM)、头孢唑肟(CZON)、米诺环素(MINO)、万古霉素(VCM)、阿贝卡星(ABK)、亚胺培南(IPM)、磷霉素(FOM)、氧氟沙星(OFLX)和克拉霉素(CAM)。对于VCM和ABK,MIC范围为0.2至12.5微克/毫升。MINO的MIC范围较宽,为0.05至25微克/毫升。所有菌株对其他抗菌药物的敏感性较低。根据凝固酶分型对这种MIC分布进行了分类评估。对于CAM,II型菌株的MIC50和MIC90≥100微克/毫升,而VII型菌株分别为0.2和3.13微克/毫升。对于比例为10比1和40比1的CZON与MINO混合组合,在静脉注射后10分钟和120分钟观察药物血药浓度、MINO与CZON之间的MIC分布。对于比例为1比1和1比4的CZON与FOM混合组合,MIC分布比单独使用FOM或CZON更敏感。关于CZON+MINO和CZON+FOM联合治疗的临床效果,在7例采用CZON+MINO治疗的UTI患者中,4例(57.1%)患者的MRSA被完全清除。在所有接受CZON+FOM治疗的患者中,该治疗方案可完全清除MRSA。在7例伤口感染和菌血症患者中的4例(57.1%),MRSA通过CZON+FOM或CZON+MINO联合治疗被清除。这些结果表明,CZON+FOM是治疗泌尿外科UTI及其他MRSA感染的有效联合方案。